Tower Research Capital (TRC)’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-20,097
| Closed | -$353K | – | 7059 |
|
|
2021
Q3 | $353K | Buy |
20,097
+16,224
| +419% | +$190K | 0.01% | 1249 |
|
|
2021
Q2 | $38K | Sell |
3,873
-909
| -19% | -$8.55K | ﹤0.01% | 3273 |
|
|
2021
Q1 | $51K | Buy |
+4,782
| New | +$59.1K | ﹤0.01% | 3118 |
|
|
2020
Q4 | – | Sell |
-4,100
| Closed | -$58K | – | 5549 |
|
|
2020
Q3 | $58K | Buy |
4,100
+2,387
| +139% | +$23.8K | ﹤0.01% | 3480 |
|
|
2020
Q2 | $14K | Buy |
+1,713
| New | +$10.6K | ﹤0.01% | 3886 |
|
|
2018
Q4 | – | Sell |
-547
| Closed | -$3K | – | 4577 |
|
|
2018
Q3 | $3K | Buy |
547
+59
| +12% | +$333 | ﹤0.01% | 3364 |
|
|
2018
Q2 | $3K | Sell |
488
-163
| -25% | -$1.04K | ﹤0.01% | 3277 |
|
|
2018
Q1 | $5K | Buy |
651
+204
| +46% | +$1.55K | ﹤0.01% | 2742 |
|
|
2017
Q4 | $3K | Buy |
447
+247
| +124% | +$2.04K | ﹤0.01% | 3135 |
|
|
2017
Q3 | $1K | Buy |
200
+100
| +100% | +$470 | ﹤0.01% | 3699 |
|
|
2017
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 2553 |
|
|
2017
Q1 | $1K | Sell |
100
-200
| -67% | -$1.17K | ﹤0.01% | 2894 |
|
|
2016
Q4 | $2K | Sell |
300
-744
| -71% | -$7.41K | ﹤0.01% | 3503 |
|
|
2016
Q3 | $21K | Buy |
1,044
+744
| +248% | +$8.57K | ﹤0.01% | 1596 |
|
|
2016
Q2 | $3K | Sell |
300
-716
| -70% | -$7.44K | ﹤0.01% | 3777 |
|
|
2016
Q1 | $9K | Buy |
1,016
+960
| +1,714% | +$8.09K | ﹤0.01% | 2110 |
|
|
2015
Q4 | $1K | Sell |
56
-17
| -23% | -$236 | ﹤0.01% | 4236 |
|
|
2015
Q3 | $1K | Sell |
73
-227
| -76% | -$4.17K | ﹤0.01% | 3730 |
|
|
2015
Q2 | $8K | Sell |
300
-900
| -75% | -$20.5K | ﹤0.01% | 2929 |
|
|
2015
Q1 | $31K | Sell |
1,200
-432
| -26% | -$6.37K | ﹤0.01% | 1888 |
|
|
2014
Q4 | $15K | Buy |
+1,632
| New | +$12.8K | ﹤0.01% | 1816 |
|
Other funds holding TRIL
Tower Research Capital (TRC)'s TRIL Position: Q4 2021 in Review
Tower Research Capital (TRC) sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 20,097 shares — an estimated $353K sold.
Tower Research Capital (TRC) first reported a position in TRIL in Q4 2014 and held it in 21 quarters. The position peaked at $353K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Tower Research Capital (TRC) reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 20,097 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $353K.
- Tower Research Capital (TRC) first reported a position in Trillium Therapeutics Inc. in Q4 2014 and held it in 21 quarters.
- Tower Research Capital (TRC)'s Trillium Therapeutics Inc. position peaked at $353K in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2021, filed 14 Feb 2022.